Go to the stock screener
Biotechnology stocks
Exelixis has the highest MEQIRI Score in Biotechnology today at 90. 22 of 289 companies are Strong.
All 289 Biotechnology stocks at MEQIRI, largest first.
As of 13 Nov 2026. How the score is calculated
Companies
289
With score
289
Average score
45
Median P/E
34.7
Median dividend
0.0%
| No. | Stock | Score | Crash risk | P/E | Dividend | Market cap |
|---|---|---|---|---|---|---|
| 1 | Vertex PharmaceuticalsVRTX | 76 | low | 34.8 | 0.0% | $137.57B |
| 2 | Regeneron PharmaceuticalsREGN | 82 | low | 20.9 | 0.4% | $98.38B |
| 3 | ModernaMRNA | 46 | Loss | 0.0% | $93.61B | |
| 4 | UCBUCB.BR | 78 | medium | 25.6 | 0.5% | $62.37B |
| 5 | argenxARGX | 70 | medium | 33.5 | 0.0% | $61.78B |
| 6 | Lonza GroupLONN.SW | 63 | medium | 43.1 | 0.8% | $55.83B |
| 7 | Samsung Biologics207940.KS | 68 | 41.4 | 0.0% | $50.56B | |
| 8 | BeOne MedicinesONC | 70 | medium | 53.3 | 0.0% | $44.45B |
| 9 | Revolution MedicinesRVMD | 41 | Loss | 0.0% | $38.14B | |
| 10 | Celltrion068270.KS | 64 | 38.5 | 0.3% | $35.82B | |
| 11 | GenmabGMAB.CO | 66 | medium | 44.5 | 0.0% | $32.18B |
| 12 | Roivant SciencesROIV | 48 | Loss | 0.0% | $28.98B | |
| 13 | InsmedINSM | 43 | high | Loss | 0.0% | $25.9B |
| 14 | WuXi Biologics (Cayman)2269.HK | 73 | 34.5 | 0.0% | $25.32B | |
| 15 | United TherapeuticsUTHR | 81 | medium | 21.8 | 0.0% | $25.27B |
| 16 | IncyteINCY | 70 | low | 61.3 | 0.0% | $24.81B |
| 17 | Alnylam PharmaceuticalsALNY | 57 | high | 7.9 | 0.0% | $20.98B |
| 18 | BioNTechBNTX | 36 | Loss | 0.0% | $20.98B | |
| 19 | Innovent Biologics1801.HK | 61 | 109.3 | 0.0% | $19.28B | |
| 20 | Ascendis PharmaASND | 69 | medium | 21.8 | 0.0% | $17.57B |
| 21 | ExelixisEXEL | 90 | low | 20.2 | 0.0% | $17.55B |
| 22 | Neurocrine BiosciencesNBIX | 77 | medium | 25.4 | 0.0% | $17.15B |
| 23 | Jazz PharmaceuticalsJAZZ | 66 | medium | 75.5*forward 9.6 | 0.0% | $15.43B |
| 24 | BridgeBio PharmaBBIO | 49 | high | Loss | 0.0% | $15.23B |
| 25 | Sichuan Kelun-Biotech Biopharmaceutical6990.HK | 49 | 712.8 | 0.0% | $13.9B | |
| 26 | Kymera TherapeuticsKYMR | 45 | Loss | 0.0% | $12.73B | |
| 27 | Madrigal PharmaceuticalsMDGL | 33 | Loss | 0.0% | $12.44B | |
| 28 | Pharmaron Beijing300759.SZ | 58 | 45.8 | 0.5% | $12.15B | |
| 29 | Summit TherapeuticsSMMT | 34 | Loss | 0.0% | $12.03B | |
| 30 | Financière de TubizeTUB.BR | 50 | low | 109.5 | 0.5% | $11.94B |
| 31 | Halozyme TherapeuticsHALO | 80 | high | 25.4 | 0.0% | $11.48B |
| 32 | Bio-TechneTECH | 64 | low | 66.9 | 0.4% | $11.44B |
| 33 | BioMarin PharmaceuticalBMRN | 48 | medium | Loss | 0.0% | $10.98B |
| 34 | Sichuan Kelun Pharmaceutical002422.SZ | 69 | 35.1 | 1.4% | $10.36B | |
| 35 | VaxcytePCVX | 44 | Loss | 0.0% | $10.24B | |
| 36 | Akeso9926.HK | 32 | Loss | 0.0% | $10.2B | |
| 37 | Haisco Pharmaceutical Group002653.SZ | 69 | 49.4 | 1.4% | $10.07B | |
| 38 | Spyre TherapeuticsSYRE | 48 | Loss | 0.0% | $9.77B | |
| 39 | TG TherapeuticsTGTX | 66 | medium | 94.9 | 0.0% | $9.76B |
| 40 | Alteogen196170.KQ | 57 | 57.4*adjusted 83.1 | 0.2% | $9.26B | |
| 41 | Genscript Biotech1548.HK | 48 | Loss | 0.0% | $9.09B | |
| 42 | Praxis Precision MedicinesPRAX | 42 | Loss | 0.0% | $9.08B | |
| 43 | Krystal BiotechKRYS | 66 | medium | 41.9 | 0.0% | $9.06B |
| 44 | Protagonist TherapeuticsPTGX | 68 | medium | 28.2 | 0.0% | $8.77B |
| 45 | Asymchem Laboratories (Tianjin)002821.SZ | 64 | 46.7 | 0.9% | $8.29B | |
| 46 | RemeGen688331.SS | 44 | 76.2 | 0.0% | $8.26B | |
| 47 | ALK-AbellóALK-B.CO | 74 | medium | 40.7 | 0.0% | $8.18B |
| 48 | AbivaxABVX.PA | 35 | Loss | 0.0% | $8B | |
| 49 | CytokineticsCYTK | 33 | Loss | 0.0% | $7.82B | |
| 50 | 10x GenomicsTXG | 43 | high | Loss | 0.0% | $7.73B |
| 51 | Rhythm PharmaceuticalsRYTM | 41 | Loss | 0.0% | $7.62B | |
| 52 | Axsome TherapeuticsAXSM | 31 | Loss | 0.0% | $7.59B | |
| 53 | Twist BioscienceTWST | 46 | high | Loss | 0.0% | $7.52B |
| 54 | ImmunovantIMVT | 45 | Loss | 0.0% | $7.25B | |
| 55 | Bachem HoldingBANB.SW | 58 | medium | 40.6 | 1.1% | $7.25B |
| 56 | Caris Life SciencesCAI | 57 | 73.6 | 0.0% | $6.87B | |
| 57 | Kodiak SciencesKOD | 43 | Loss | 0.0% | $6.8B | |
| 58 | Belite BioBLTE | 45 | Loss | 0.0% | $6.76B | |
| 59 | Arrowhead PharmaceuticalsARWR | 30 | Loss | 0.0% | $6.66B | |
| 60 | ImmunityBioIBRX | 37 | Loss | 0.0% | $6.46B | |
| 61 | BioconBIOCON.NS | 41 | 133.7*forward 40.2 | 0.1% | $6.42B | |
| 62 | Samsung Epis Holdings0126Z0.KS | 41 | 18.2 | 0.0% | $6.4B | |
| 63 | Ligand PharmaceuticalsLGND | 60 | medium | 122.7*adjusted 36.4 | 0.0% | $6.33B |
| 64 | CG OncologyCGON | 41 | Loss | 0.0% | $6.27B | |
| 65 | Hangzhou Tigermed Consulting300347.SZ | 46 | Loss | 0.3% | $6.12B | |
| 66 | Mirum PharmaceuticalsMIRM | 38 | high | Loss | 0.0% | $6.09B |
| 67 | Scholar Rock HoldingSRRK | 35 | Loss | 0.0% | $5.71B | |
| 68 | Anthem BiosciencesANTHEM.NS | 78 | 86.9 | 0.2% | $5.62B | |
| 69 | Shanghai Allist Pharmaceuticals688578.SS | 66 | 12.9 | 1.4% | $5.61B | |
| 70 | ErascaERAS | 44 | Loss | 0.0% | $5.52B | |
| 71 | PTC TherapeuticsPTCT | 46 | high | Loss | 0.0% | $5.29B |
| 72 | Dianthus TherapeuticsDNTH | 46 | Loss | 0.0% | $5.21B | |
| 73 | SK Biopharmaceuticals326030.KS | 67 | 18.0 | 0.0% | $5.14B | |
| 74 | Cogent BiosciencesCOGT | 28 | Loss | 0.0% | $5.07B | |
| 75 | Travere TherapeuticsTVTX | 50 | high | Loss | 0.0% | $4.95B |
| 76 | Edgewise TherapeuticsEWTX | 54 | medium | 4.9 | 0.0% | $4.93B |
| 77 | Adaptive BiotechnologiesADPT | 47 | Loss | 0.0% | $4.77B | |
| 78 | Ionis PharmaceuticalsIONS | 32 | high | Loss | 0.0% | $4.55B |
| 79 | Definium TherapeuticsDFTX | 41 | Loss | 0.0% | $4.52B | |
| 80 | CamurusCAMX.ST | 74 | medium | 58.3 | 0.0% | $4.41B |
| 81 | Tango TherapeuticsTNGX | 46 | Loss | 0.0% | $4.21B | |
| 82 | CRISPR TherapeuticsCRSP | 34 | Loss | 0.0% | $4.13B | |
| 83 | Xenon PharmaceuticalsXENE | 35 | Loss | 0.0% | $4.03B | |
| 84 | Relay TherapeuticsRLAY | 43 | Loss | 0.0% | $3.99B | |
| 85 | Amylyx PharmaceuticalsAMLX | 43 | Loss | 0.0% | $3.84B | |
| 86 | AbCellera BiologicsABCL | 37 | Loss | 0.0% | $3.8B | |
| 87 | Tarsus PharmaceuticalsTARS | 42 | Loss | 0.0% | $3.79B | |
| 88 | Denali TherapeuticsDNLI | 35 | Loss | 0.0% | $3.56B | |
| 89 | Enliven TherapeuticsELVN | 44 | Loss | 0.0% | $3.56B | |
| 90 | CelcuityCELC | 29 | Loss | 0.0% | $3.54B | |
| 91 | Iovance BiotherapeuticsIOVA | 43 | Loss | 0.0% | $3.53B | |
| 92 | Viking TherapeuticsVKTX | 33 | Loss | 0.0% | $3.52B | |
| 93 | Arcutis BiotherapeuticsARQT | 61 | medium | 126.0 | 0.0% | $3.48B |
| 94 | Viridian TherapeuticsVRDN | 47 | Loss | 0.0% | $3.46B | |
| 95 | Legend BiotechLEGN | 36 | high | Loss | 0.0% | $3.43B |
| 96 | Disc MedicineIRON | 41 | Loss | 0.0% | $3.2B | |
| 97 | Dyne TherapeuticsDYN | 34 | Loss | 0.0% | $3.19B | |
| 98 | Telix PharmaceuticalsTLX | 39 | high | 99.9 | 0.0% | $3.18B |
| 99 | Acadia PharmaceuticalsACAD | 62 | high | 8.8 | 0.0% | $3.14B |
| 100 | IDEAYA BiosciencesIDYA | 38 | Loss | 0.0% | $3.04B | |
| 101 | Xeris Biopharma HoldingsXERS | 55 | high | Loss | 0.0% | $3.04B |
| 102 | Zai LabZLAB | 50 | Loss | 0.0% | $2.94B | |
| 103 | ADMA BiologicsADMA | 71 | high | 16.4 | 0.0% | $2.94B |
| 104 | VericelVCEL | 66 | high | 91.3 | 0.0% | $2.93B |
| 105 | XencorXNCR | 47 | Loss | 0.0% | $2.86B | |
| 106 | BioArcticBIOA-B.ST | 59 | medium | 263.3 | 0.6% | $2.79B |
| 107 | MBX BiosciencesMBX | 46 | Loss | 0.0% | $2.71B | |
| 108 | Bavarian NordicBAVA.CO | 71 | medium | 11.8 | 0.0% | $2.7B |
| 109 | Arcus BiosciencesRCUS | 30 | Loss | 0.0% | $2.56B | |
| 110 | Beam TherapeuticsBEAM | 38 | Loss | 0.0% | $2.49B | |
| 111 | NewAmsterdam PharmaNAMS | 35 | Loss | 0.0% | $2.4B | |
| 112 | PharvarisPHVS | 44 | Loss | 0.0% | $2.38B | |
| 113 | Zealand PharmaZEAL.CO | 59 | high | 6.2 | 0.0% | $2.37B |
| 114 | Replimune GroupREPL | 42 | Loss | 0.0% | $2.31B | |
| 115 | Lakefront BiotherapeuticsLKFT | 74 | medium | 3.6 | 0.0% | $2.26B |
| 116 | Celldex TherapeuticsCLDX | 34 | Loss | 0.0% | $2.24B | |
| 117 | Palvella TherapeuticsPVLA | 44 | Loss | 0.0% | $2.24B | |
| 118 | ImmunomeIMNM | 36 | Loss | 0.0% | $2.21B | |
| 119 | Alamar BiosciencesALMR | 47 | Loss | 0.0% | $2.21B | |
| 120 | Maze TherapeuticsMAZE | 45 | Loss | 0.0% | $2.2B | |
| 121 | Maravai LifeSciences HoldingsMRVI | 38 | Loss | 0.0% | $2.18B | |
| 122 | Trevi TherapeuticsTRVI | 38 | Loss | 0.0% | $2.18B | |
| 123 | Aurinia PharmaceuticalsAUPH | 69 | medium | 7.0*adjusted 15.9 | 0.0% | $2.17B |
| 124 | BiohavenBHVN | 42 | Loss | 0.0% | $2.13B | |
| 125 | Vera TherapeuticsVERA | 35 | Loss | 0.0% | $2.1B | |
| 126 | Vir BiotechnologyVIR | 52 | Loss | 0.0% | $2.08B | |
| 127 | Recursion PharmaceuticalsRXRX | 36 | Loss | 0.0% | $2.07B | |
| 128 | First Tracks BiotherapeuticsTRAX | 48 | Loss | 0.0% | $2.05B | |
| 129 | SepternaSEPN | 49 | Loss | 0.0% | $1.99B | |
| 130 | Harmony Biosciences HoldingsHRMY | 72 | medium | 11.3 | 0.0% | $1.98B |
| 131 | BioCryst PharmaceuticalsBCRX | 37 | Loss | 0.0% | $1.98B | |
| 132 | Agios PharmaceuticalsAGIO | 39 | Loss | 0.0% | $1.9B | |
| 133 | Fortrea HoldingsFTRE | 41 | high | Loss | 0.0% | $1.9B |
| 134 | Zenas BioPharmaZBIO | 37 | Loss | 0.0% | $1.87B | |
| 135 | ZymeworksZYME | 59 | high | 46.7 | 0.0% | $1.84B |
| 136 | Hemab Therapeutics HoldingsCOAG | 45 | Loss | 0.0% | $1.84B | |
| 137 | uniQureQURE | 35 | Loss | 0.0% | $1.73B | |
| 138 | Sarepta TherapeuticsSRPT | 39 | high | 114.9*forward 22.5 | 0.0% | $1.72B |
| 139 | Kailera TherapeuticsKLRA | 41 | Loss | 0.0% | $1.72B | |
| 140 | Stoke TherapeuticsSTOK | 37 | high | Loss | 0.0% | $1.71B |
| 141 | Taysha Gene TherapiesTSHA | 35 | Loss | 0.0% | $1.71B | |
| 142 | Nurix TherapeuticsNRIX | 68 | high | 6.1 | 0.0% | $1.7B |
| 143 | MesoblastMESO | 37 | Loss | 0.0% | $1.7B | |
| 144 | PrecigenPGEN | 54 | high | 80.4 | 0.0% | $1.67B |
| 145 | Ultragenyx PharmaceuticalRARE | 38 | high | Loss | 0.0% | $1.66B |
| 146 | NanobiotixNANO.PA | 38 | Loss | 0.0% | $1.64B | |
| 147 | SELLAS Life Sciences GroupSLS | 35 | Loss | 0.0% | $1.62B | |
| 148 | Generate BiomedicinesGENB | 36 | Loss | 0.0% | $1.61B | |
| 149 | Immunocore HoldingsIMCR | 45 | high | Loss | 0.0% | $1.57B |
| 150 | AbsciABSI | 38 | Loss | 0.0% | $1.57B | |
| 151 | Intellia TherapeuticsNTLA | 33 | Loss | 0.0% | $1.48B | |
| 152 | NovavaxNVAX | 42 | Loss | 0.0% | $1.45B | |
| 153 | Nuvation BioNUVB | 29 | Loss | 0.0% | $1.43B | |
| 154 | AnaptysBioANAB | 60 | high | 9.4 | 0.0% | $1.43B |
| 155 | Alto NeuroscienceANRO | 41 | Loss | 0.0% | $1.42B | |
| 156 | Ascentage Pharma Group InternationalAAPG | 37 | Loss | 0.0% | $1.4B | |
| 157 | Ocular TherapeutixOCUL | 34 | Loss | 0.0% | $1.38B | |
| 158 | LB PharmaceuticalsLBRX | 49 | Loss | 0.0% | $1.37B | |
| 159 | Mineralys TherapeuticsMLYS | 29 | Loss | 0.0% | $1.37B | |
| 160 | Damora TherapeuticsDMRA | 38 | Loss | 0.0% | $1.36B | |
| 161 | Tyra BiosciencesTYRA | 36 | Loss | 0.0% | $1.36B | |
| 162 | Avalyn PharmaAVLN | 41 | Loss | 0.0% | $1.36B | |
| 163 | InnovivaINVA | 67 | medium | 7.0*adjusted 7.6 | 0.0% | $1.35B |
| 164 | MannKindMNKD | 39 | high | Loss | 0.0% | $1.34B |
| 165 | Pharma MarPHM.MC | 59 | medium | 17.3 | 1.5% | $1.31B |
| 166 | OmerosOMER | 52 | high | 13.8*adjusted 7.0 | 0.0% | $1.3B |
| 167 | UroGen PharmaURGN | 36 | Loss | 0.0% | $1.29B | |
| 168 | Inhibrx BiosciencesINBX | 33 | Loss | 0.0% | $1.29B | |
| 169 | COMPASS PathwaysCMPS | 35 | Loss | 0.0% | $1.28B | |
| 170 | IdorsiaIDIA.SW | 35 | Loss | 0.0% | $1.28B | |
| 171 | Nektar TherapeuticsNKTR | 29 | Loss | 0.0% | $1.27B | |
| 172 | GH ResearchGHRS | 36 | Loss | 0.0% | $1.27B | |
| 173 | KardiganKARD | 44 | Loss | 0.0% | $1.26B | |
| 174 | Rapport TherapeuticsRAPP | 33 | Loss | 0.0% | $1.24B | |
| 175 | Alpha Tau MedicalDRTS | 42 | Loss | 0.0% | $1.24B | |
| 176 | SavaraSVRA | 33 | Loss | 0.0% | $1.2B | |
| 177 | MedinCellMEDCL.PA | 47 | high | Loss | 0.0% | $1.16B |
| 178 | Structure TherapeuticsGPCR | 31 | Loss | 0.0% | $1.14B | |
| 179 | SpyGlass PharmaSGP | 47 | Loss | 0.0% | $1.11B | |
| 180 | MoonLake ImmunotherapeuticsMLTX | 35 | Loss | 0.0% | $1.1B | |
| 181 | InventivaIVA.PA | 31 | Loss | 0.0% | $1.09B | |
| 182 | Seaport TherapeuticsSPTX | 46 | Loss | 0.0% | $1.08B | |
| 183 | Basilea PharmaceuticaBSLN.SW | 74 | low | 18.9 | 0.0% | $1.07B |
| 184 | VerastemVSTM | 40 | Loss | 0.0% | $1.06B | |
| 185 | Solid BiosciencesSLDB | 39 | Loss | 0.0% | $1.06B | |
| 186 | Vor BiopharmaVOR | 47 | Loss | 0.0% | $1.05B | |
| 187 | Jade BiosciencesJBIO | 42 | Loss | 0.0% | $1.01B | |
| 188 | Corvus PharmaceuticalsCRVS | 37 | Loss | 0.0% | $982.22M | |
| 189 | ImmaticsIMTX | 28 | Loss | 0.0% | $975.63M | |
| 190 | Odyssey TherapeuticsODTX | 44 | Loss | 0.0% | $966.16M | |
| 191 | PhilogenPHIL.MI | 68 | medium | 3.8 | 3.3% | $948.15M |
| 192 | Monte Rosa TherapeuticsGLUE | 32 | Loss | 0.0% | $947.69M | |
| 193 | Silence TherapeuticsSLN | 45 | Loss | 0.0% | $935.23M | |
| 194 | Pharming GroupPHARM.AS | 49 | medium | 39.4 | 0.0% | $910.96M |
| 195 | ORIC PharmaceuticalsORIC | 32 | Loss | 0.0% | $881.05M | |
| 196 | 4D Molecular TherapeuticsFDMT | 47 | Loss | 0.0% | $875.68M | |
| 197 | Aktis OncologyAKTS | 36 | Loss | 0.0% | $875M | |
| 198 | Climb BioCLYM | 41 | Loss | 0.0% | $869.94M | |
| 199 | Rigel PharmaceuticalsRIGL | 71 | high | 3.0*adjusted 14.7 | 0.0% | $860.34M |
| 200 | Syndax PharmaceuticalsSNDX | 33 | high | Loss | 0.0% | $858.87M |
| 201 | MeiraGTx HoldingsMGTX | 40 | Loss | 0.0% | $844.22M | |
| 202 | AnnexonANNX | 36 | Loss | 0.0% | $812.47M | |
| 203 | Lexicon PharmaceuticalsLXRX | 39 | Loss | 0.0% | $810.33M | |
| 204 | Arbutus BiopharmaABUS | 66 | medium | 3.7 | 0.0% | $798.37M |
| 205 | AlumisALMS | 38 | Loss | 0.0% | $793.44M | |
| 206 | ArdelyxARDX | 34 | Loss | 0.0% | $784.28M | |
| 207 | Olema PharmaceuticalsOLMA | 34 | Loss | 0.0% | $760.22M | |
| 208 | GubraGUBRA.CO | 43 | high | Loss | 0.0% | $738.91M |
| 209 | DBV TechnologiesDBV.PA | 40 | Loss | 0.0% | $738.12M | |
| 210 | Aura BiosciencesAURA | 41 | Loss | 0.0% | $737.34M | |
| 211 | Attovia TherapeuticsATTO | 44 | Loss | 0.0% | $722.72M | |
| 212 | OmniAbOABI | 54 | high | Loss | 0.0% | $722.01M |
| 213 | Prime MedicinePRME | 37 | Loss | 0.0% | $705.56M | |
| 214 | Janux TherapeuticsJANX | 33 | Loss | 0.0% | $703.61M | |
| 215 | Achieve Life SciencesACHV | 41 | Loss | 0.0% | $697.68M | |
| 216 | Nuvectis PharmaNVCT | 46 | Loss | 0.0% | $695.69M | |
| 217 | Ginkgo Bioworks HoldingsDNA | 41 | Loss | 0.0% | $688.89M | |
| 218 | Kura OncologyKURA | 27 | Loss | 0.0% | $682.66M | |
| 219 | Design TherapeuticsDSGN | 37 | Loss | 0.0% | $677.5M | |
| 220 | ArriVent BioPharmaAVBP | 29 | Loss | 0.0% | $676.02M | |
| 221 | Bicara TherapeuticsBCAX | 31 | Loss | 0.0% | $671.17M | |
| 222 | Immix BiopharmaIMMX | 38 | Loss | 0.0% | $669.03M | |
| 223 | Zevra TherapeuticsZVRA | 72 | high | 8.8 | 0.0% | $664.07M |
| 224 | Candel TherapeuticsCADL | 35 | Loss | 0.0% | $641.99M | |
| 225 | GeronGERN | 34 | Loss | 0.0% | $640.37M | |
| 226 | Aclaris TherapeuticsACRS | 39 | Loss | 0.0% | $634.45M | |
| 227 | Cullinan TherapeuticsCGEM | 34 | Loss | 0.0% | $626.26M | |
| 228 | Wave Life SciencesWVE | 38 | Loss | 0.0% | $623.24M | |
| 229 | Monopar TherapeuticsMNPR | 42 | Loss | 0.0% | $622.21M | |
| 230 | Sana BiotechnologySANA | 29 | Loss | 0.0% | $602.27M | |
| 231 | GenfitGNFT.PA | 44 | Loss | 0.0% | $601.03M | |
| 232 | Capricor TherapeuticsCAPR | 33 | Loss | 0.0% | $593.02M | |
| 233 | Entera BioENTX | 44 | Loss | 0.0% | $560.72M | |
| 234 | Adlai NortyeANL | 36 | Loss | 0.0% | $558.4M | |
| 235 | ValnevaVLA.PA | 29 | Loss | 0.0% | $554.46M | |
| 236 | Helus PharmaHELP | 39 | Loss | 0.0% | $549.18M | |
| 237 | Crescent BiopharmaCBIO | 33 | Loss | 0.0% | $533.76M | |
| 238 | REGENXBIORGNX | 34 | Loss | 0.0% | $530.96M | |
| 239 | Eupraxia PharmaceuticalsEPRX | 44 | Loss | 0.0% | $525.16M | |
| 240 | Egetis TherapeuticsEGTX.ST | 42 | high | Loss | 0.0% | $518.45M |
| 241 | Phathom PharmaceuticalsPHAT | 29 | Loss | 0.0% | $506.45M | |
| 242 | DiaMedica TherapeuticsDMAC | 46 | Loss | 0.0% | $503.13M | |
| 243 | Shattuck LabsSTTK | 31 | Loss | 0.0% | $489.86M | |
| 244 | Ovid TherapeuticsOVID | 43 | Loss | 0.0% | $481.27M | |
| 245 | MiMedx GroupMDXG | 37 | Loss | 0.0% | $472.8M | |
| 246 | Hansa BiopharmaHNSA.ST | 47 | Loss | 0.0% | $472.24M | |
| 247 | Oculis HoldingOCS | 30 | Loss | 0.0% | $462.99M | |
| 248 | Gyre TherapeuticsGYRE | 35 | Loss | 0.0% | $455.95M | |
| 249 | ArvinasARVN | 37 | Loss | 0.0% | $449.88M | |
| 250 | Avalo TherapeuticsAVTX | 34 | Loss | 0.0% | $445.24M | |
| 251 | CytomX TherapeuticsCTMX | 31 | Loss | 0.0% | $444.73M | |
| 252 | Relmada TherapeuticsRLMD | 37 | Loss | 0.0% | $443.75M | |
| 253 | BlossomHill TherapeuticsBLSM | 41 | Loss | 0.0% | $431.56M | |
| 254 | AgenusAGEN | 50 | high | 19.4*adjusted 4.3 | 0.0% | $430.39M |
| 255 | Benitec BiopharmaBNTC | 30 | Loss | 0.0% | $423.21M | |
| 256 | ProthenaPRTA | 40 | Loss | 0.0% | $422.61M | |
| 257 | Puma BiotechnologyPBYI | 61 | high | 18.0 | 0.0% | $417.72M |
| 258 | Tectonic TherapeuticTECX | 33 | Loss | 0.0% | $411.32M | |
| 259 | Assembly BiosciencesASMB | 34 | Loss | 0.0% | $410.88M | |
| 260 | RezoluteRZLT | 37 | Loss | 0.0% | $405.49M | |
| 261 | X4 PharmaceuticalsXFOR | 37 | Loss | 0.0% | $401.08M | |
| 262 | ProKidneyPROK | 27 | Loss | 0.0% | $386.69M | |
| 263 | Lyell ImmunopharmaLYEL | 33 | Loss | 0.0% | $384.52M | |
| 264 | ARS PharmaceuticalsSPRY | 33 | Loss | 0.0% | $383.01M | |
| 265 | Fennec PharmaceuticalsFENC | 56 | high | 204.8 | 0.0% | $382.23M |
| 266 | NeurogeneNGNE | 32 | Loss | 0.0% | $377.68M | |
| 267 | CorMedixCRMD | 56 | high | 5.9 | 0.0% | $377.25M |
| 268 | Contineum TherapeuticsCTNM | 35 | Loss | 0.0% | $375.46M | |
| 269 | Orchestra BioMed HoldingsOBIO | 50 | Loss | 0.0% | $369.65M | |
| 270 | YD BioYDES | 36 | Loss | 0.0% | $368.32M | |
| 271 | AlectorALEC | 71 | high | 6.6 | 0.0% | $364.75M |
| 272 | C4 TherapeuticsCCCC | 34 | Loss | 0.0% | $363.75M | |
| 273 | Sagimet BiosciencesSGMT | 45 | Loss | 0.0% | $356.12M | |
| 274 | PepGenPEPG | 42 | Loss | 0.0% | $348.61M | |
| 275 | Atea PharmaceuticalsAVIR | 35 | Loss | 0.0% | $338.08M | |
| 276 | Opus GeneticsIRD | 42 | Loss | 0.0% | $337.77M | |
| 277 | Editas MedicineEDIT | 25 | Loss | 0.0% | $330.29M | |
| 278 | Eikon TherapeuticsEIKN | 33 | Loss | 0.0% | $327M | |
| 279 | Enanta PharmaceuticalsENTA | 27 | Loss | 0.0% | $326.2M | |
| 280 | Autolus TherapeuticsAUTL | 30 | Loss | 0.0% | $316.73M | |
| 281 | AgomAb TherapeuticsAGMB | 30 | Loss | 0.0% | $313.22M | |
| 282 | AltimmuneALT | 24 | Loss | 0.0% | $313.17M | |
| 283 | Kyverna TherapeuticsKYTX | 28 | Loss | 0.0% | $311.07M | |
| 284 | Vicore Pharma HoldingVICO.ST | 38 | Loss | 0.0% | $310.09M | |
| 285 | Turn TherapeuticsTTRX | 44 | Loss | 0.0% | $307.62M | |
| 286 | Nautilus BiotechnolgyNAUT | 40 | Loss | 0.0% | $303.15M | |
| 287 | MapLight TherapeuticsMPLT | 32 | Loss | 0.0% | $301.31M | |
| 288 | FormyconFYB.DE | 30 | high | Loss | 0.0% | $293.75M |
| 289 | Heidelberg PharmaHPHA.DE | 28 | Loss | 0.0% | $105.76M |
* P/E with one-off items or after a one-time drop in earnings. Below it is the adjusted or the forward P/E. The P/E then does not count in the score.